LGLorne J. Gula

Lorne J. Gula

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lorne J. Gula has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A simple maneuver to determine if septal accessory pathway ablation requires a left atrial approach

    by Juliana Kanawati, Jason D. Roberts, Matthew K. Rowe, Habib Khan, William K. Chan, Peter Leong‐Sit, Jaimie Manlucu, Raymond Yee, Anthony S. Tang, Lorne J. Gula, et al.

    Introduction: Septal accessory pathway (AP) ablation can be challenging due to the complex anatomy of the septal region. The decision to access the left atrium (LA) is often made after failure of ablation from the right. We sought to establish whether the difference between ventriculo‐atrial (VA) time during right ventricular (RV) apical pacing versus the VA during tachycardia would help establish the successful site for ablation of septal APs.Methods: Intracardiac electrograms of patients with orthodromic reciprocating tachycardia (ORT) using a septal AP with successful catheter ablation were reviewed. The ∆VA was the difference between the VA interval during RV apical pacing and the VA interval during ORT. The difference in the VA interval during right ventricular entrainment and ORT (StimA–VA) was also measured.Results: The median ∆VA time was significantly less in patients with a septal AP ablated on the right side compared with patients with a septal AP ablated on the left side (12 ± 19 vs. 56 ± 10 ms, p < .001). The StimA–VA was significantly different between the two groups (22 ± 14 vs. 53 ± 9 ms, p < .001). The ∆VA and StimA–VA were always 40 ms in patients with non‐decremental septal APs ablated from the right side and always greater than 40 ms in those with septal APs ablated from the left.Conclusion: ΔVA and StimA–VA values identified with RV apical pacing in the setting of ORT involving a septal AP predict when left atrial access will be necessary for successful ablation.


  • Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH

    by Lorne J. Gula, Steve Doucette, Peter Leong‐Sit, Anthony S.L. Tang, Ratika Parkash, Jean‐Francois Sarrazin, Bernard Thibault, Vidal Essebag, Stanley K. Tung, Marc W. Deyell, et al.

    Background/objective: We compared health‐related quality of life (HRQoL) in patients randomized to escalated therapy and those randomized to ablation for ventricular tachycardia in the VANISH trial.Methods: HRQoL was assessed among VANISH patients at baseline and 3‐, 6‐, and 12‐month follow‐up visits. Four validated instruments were used: the SF‐36, the implanted cardioverter defibrillator (ICD) Concerns questionnaire (ICDC), the Hospital Anxiety and Depression Scale (HADS), and the EuroQol five dimensions questionnaire (EQ‐5D). Linear mixed‐effects modeling was used for repeated measures with SF‐36, HADS, ICDC, and EQ‐5D as dependent variables. In a second model, treatment was subdivided by amiodarone use prior to enrollment.Results: HRQoL did not differ significantly between those randomized to ablation or escalated therapy. On subgroup analysis, improvement in SF‐36 measures was seen at 6 months in the ablation group for social functioning (63.5–69.3, P = 0.03) and energy/fatigue (43.0–47.9, P = 0.01). ICDC measures showed a reduction in ICD concern in the ablation group at 6 months (10.4–8.7, P = 0.01) and a reduction in ICD concern in the escalated therapy group at 6 months (10.9–9.4, P = 0.04). EQ‐5D measures showed a significant improvement in overall health in ablation patients at 6 months (63.4–67.3, P = 0.04).Conclusion: Patients in the VANISH study randomized to ablation did not have a significant change in quality of life outcomes compared to those randomized to escalated therapy. Some subgroup findings were significant, as those randomized to ablation showed persistent improvement in SF‐36 energy/fatigue and ICD concern, and transient improvement in SF‐36 social functioning and EQ‐5D overall health.


  • Charting a Course for Cardiac Electrophysiology Training in Canada: The Vital Role of Fellows in Advanced Cardiovascular Care

    by Richard A. Leather, Martin Gardner, Martin S. Green, Katherine Kavanagh, Laurent Macle, Kamran Ahmad, Chris Gray, Felix Ayala-Paredes, Peter G. Guerra, Gilles O'Hara, et al.


  • Asymptomatic Wolff-Parkinson-White Syndrome: Who Should Be Treated?

    by Manoj N. Obeyesekere, Peter Leong-Sit, Andrew D. Krahn, Lorne J. Gula, Raymond Yee, Allan C. Skanes, George J. Klein


  • The Evaluation of a Borderline Long QT Interval in an Asymptomatic Patient

    by Manoj N. Obeyesekere, Peter Leong-Sit, Lorne J. Gula, Raymond Yee, Allan C. Skanes, George J. Klein, Andrew D. Krahn


    • 1 January 2011
      • Vol. 18  (2) , 210-6

    How to diagnose the cause of sudden cardiac arrest.

    by Hoong Sern Lim, Rajesh N Subbiah, Peter Leong-Sit, Lorne J Gula, Allan C Skanes, Raymond Yee, George J Klein, Andrew D Krahn

    Sudden cardiac death or sudden cardiac arrest (SCA) is defined as natural death that occurs within an hour of the onset of acute symptoms or during sleep due to a primary cardiac cause. Most cases of SCA are attributable to coronary artery disease, with occult cardiomyopathy or inheritable arrhythmic syndromes accounting for a minority of SCA. Diagnosing the cause of SCA has potential implications for the patient and the family, and demands a comprehensive approach. This review summarizes the potential causes of SCA and outlines a systematic diagnostic approach to the SCA survivor.

  • Expression of a Common LQT1 Mutation in Five Apparently Unrelated Families in a Regional Inherited Arrhythmia Clinic

    by Christopher Gray, Lorne J. Gula, George J. Klein, Allan C. Skanes, Raymond Yee, Raymond Sy, Benjamin A. Salisbury, Jorge Wong, Ishvinder Chattha, Rajesh N. Subbiah, et al.

    Expression of a Common LQT1 Mutation. Background: The Inherited Arrhythmia Clinic at the University of Western Ontario services a catchment area of 1.5 million people and follows families with inherited arrhythmia syndromes. Methods: Patients referred for evaluation of long‐QT Syndrome (LQTS) are evaluated with resting and standing ECGs, and treadmill exercise testing. Patients with findings consistent with LQTS are offered comprehensive genetic testing with screening of all first‐degree relatives of genotype‐positive patients. Results: Among 31 probands with disease‐causing LQTS mutations, 5 probands from apparently unrelated families of Irish descent were found to have an identical disease causing transmembrane mutation in KCNQ1 (Leu266Pro). Systematic screening of 33 first‐degree relatives of genotype‐positive individuals detected 15 unaffected and 18 asymptomatic affected family members. Symptoms in 6 patients occurred later in life than reported LQT1 populations (61 ± 18 years, range 44–89). In this cohort, several family members presented with cardiac arrest during acute myocardial ischemia (n = 2), sudden death, unexplained drowning, and torsade de pointes during exercise testing. There was no identifiable common relative for this cohort after pedigree construction of the previous 4–7 generations. Affected patients had mild QT prolongation at rest with dramatic QT prolongation with exercise. Conclusions: Genetic testing in this LQTS population suggests a common KCNQ1 Leu266Pro founder effect, with the descendants clustering in our geographical region even though no common relative has been identified. The observations highlight the utility of genotypic and phenotypic correlation and a specialized clinic. (J Cardiovasc Electrophysiol, Vol. 21, pp. 296–300, March 2010)


  • Supraventricular tachycardia: diagnosis and management.

    by David J Fox, Alexander Tischenko, Andrew D Krahn, Allan C Skanes, Lorne J Gula, Raymond K Yee, George J Klein

    Supraventricular tachycardia (SVT) includes all forms of tachycardia that either arise above the bifurcation of the bundle of His or that have mechanisms dependent on the bundle of His. We conducted a review of the techniques used to differentiate the mechanisms of SVT. We searched the PubMed and MEDLINE databases for English-language literature published from 1970 to 2008. Articles were selected for either their historical importance or up-to-date clinical data. This review focuses on techniques for scrutinizing electrocardiograms of patients, analyzing in particular the onset of tachycardia, the mode of tachycardia termination, and the effects of premature ventricular contractions, premature atrial contractions, and aberrancy during tachycardia. Both short-term and long-term management of SVT are examined, including the urgent treatment of patients in the emergency department. This review also describes management of patients who have ongoing symptomatic SVT, outlining such available treatment options as atrioventricular node-blocking drugs, antiarrhythmic drugs, and catheter ablation.


    • 1 January 2007
      • Vol. 14  (2) , 113-4

    Not so fast.

    by Lorne J Gula, Andrew D Krahn

  • A Classic but Uncommon Principle

    by Emoke Posan, Lorne J. Gula, Allan C. Skanes, Andrew D. Krahn, Raymond Yee, George J. Klein